# Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy

> **NCT06666634** · NA · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 29 (estimated)

## Conditions studied

- Penile Cancer
- Melanoma
- Oral Cancer

## Interventions

- **DRUG:** Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan

## Key facts

- **NCT ID:** NCT06666634
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-01
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06666634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06666634, "Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT06666634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*